|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.03 USD | +1.28% |
|
+1.13% | -1.88% |
| 12-06 | Pfizer Inc. Presents Results from the Phase 3 BASIS Study Evaluating HYMPAVZI for Adults and Adolescents | CI |
| 12-03 | Mizuho's Katz sees 'fertile' conditions driving robust M&A market into 2026 | RE |
| Capitalization | 148B 127B 119B 111B 205B 13,320B 223B 1,394B 538B 6,291B 555B 544B 23,002B | P/E ratio 2025 * |
13.5x | P/E ratio 2026 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise value | 189B 162B 152B 142B 261B 16,973B 284B 1,776B 686B 8,016B 708B 693B 29,310B | EV / Sales 2025 * |
3.02x | EV / Sales 2026 * | 2.98x |
| Free-Float |
59.04% | Yield 2025 * |
6.55% | Yield 2026 * | 6.69% |
Last Transcript: Pfizer Inc.
| 1 day | +1.28% | ||
| 1 week | +1.13% | ||
| Current month | +1.13% | ||
| 1 month | +4.75% | ||
| 3 months | +4.62% | ||
| 6 months | +11.48% | ||
| Current year | -1.88% |
| 1 week | 25.04 |  | 26.12 |
| 1 month | 23.91 | | 26.48 |
| Current year | 20.92 | | 27.69 |
| 1 year | 20.92 | | 27.69 |
| 3 years | 20.92 | | 54.93 |
| 5 years | 20.92 | | 61.71 |
| 10 years | 20.92 | | 61.71 |
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 63 | 2018-12-31 |
David Denton
DFI | Director of Finance/CFO | 60 | 2022-05-01 |
| Chief Tech/Sci/R&D Officer | - | 2025-02-23 |
| Director | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 67 | 2007-08-31 |
Shantanu Narayen
BRD | Director/Board Member | 61 | 2013-09-26 |
Albert Bourla
CHM | Chairman | 63 | 2019-12-31 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 14.74% | 303 M€ | -21.21% | - |
| 9.37% | 26 M€ | +11.73% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.28% | +1.13% | +1.17% | -47.64% | 148B | |
| -0.41% | -6.06% | +22.21% | +174.14% | 905B | |
| -0.27% | -2.41% | +35.24% | +14.67% | 487B | |
| -1.15% | -0.71% | +28.32% | +38.09% | 400B | |
| +0.26% | +1.14% | +20.97% | +1.87% | 330B | |
| +0.58% | -2.73% | +27.58% | +21.90% | 281B | |
| +0.19% | +2.49% | +19.23% | +25.56% | 255B | |
| -1.16% | -4.87% | -3.27% | -8.45% | 248B | |
| +1.24% | -2.33% | -60.59% | -30.82% | 214B | |
| -3.02% | -4.51% | +21.03% | +16.45% | 178B | |
| Average | -0.25% | -1.89% | +11.19% | +20.58% | 344.45B | |
| Weighted average by Cap. | -0.30% | -2.62% | +16.91% | +52.36% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 62.54B 53.76B 50.36B 46.94B 86.7B 5,629B 94.3B 589B 227B 2,658B 235B 230B 9,720B | 61.81B 53.13B 49.78B 46.39B 85.69B 5,563B 93.21B 582B 225B 2,627B 232B 227B 9,607B |
| Net income | 11.1B 9.54B 8.94B 8.33B 15.39B 999B 16.74B 105B 40.38B 472B 41.67B 40.78B 1,726B | 13.05B 11.22B 10.51B 9.8B 18.09B 1,175B 19.68B 123B 47.47B 555B 48.99B 47.94B 2,028B |
| Net Debt | 40.59B 34.89B 32.69B 30.47B 56.27B 3,653B 61.21B 382B 148B 1,725B 152B 149B 6,309B | 36.19B 31.11B 29.14B 27.16B 50.17B 3,257B 54.57B 341B 132B 1,538B 136B 133B 5,624B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 26.03 $ | +1.28% | 47,443,701 |
| 25-12-04 | 25.70 $ | +0.51% | 35,453,966 |
| 25-12-03 | 25.57 $ | +1.67% | 56,121,174 |
| 25-12-02 | 25.15 $ | -0.47% | 43,826,986 |
| 25-12-01 | 25.27 $ | -1.83% | 53,198,560 |
Delayed Quote Nyse, December 05, 2025 at 04:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PFE Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition